The FDA recently approved of the generic versions of Cymbalta and this is approval takes effect today. The generic will be manufactured by five different generic pharmaceutical companies. It is important for patients taking this medication to understand the generic bioequivalence have a range of 80 – 120% of the brand bioavailability. While the transition from a brand to generic formulation often occurs without relapse, occasionally some patients may notice a decline in the effectiveness of the medication with a change to generic. It’s best to carefully monitor your symptoms and side effects during the first month of transition from brand formulation to a generic preparation.